Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (March 2026)
23 slides from Oncolytics Biotech's investor presentation, March 2026
Slide 1: Pelareorep: a transformative dsRNA immunotherapy platform for gastrointestinal tumors
PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors March 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Confidential This presentation is strictly confidential. Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representation to the contrary
Slide 3: Mission
MISSION We will leverage our proprietary product candidate, pelareorep (pela), an investigational first-in-class double-stranded RNA immunotherapeutic agent, to establish a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI tumors are the largest unmet medical ne
Slide 4: Pelareorep Proposed Mechanism of Action
PELAREOREP PROPOSED MECHANISM OF ACTION Pela infection kills some tumor cells by cell lysis and Intravenous pela evades neutralization by Pela selectively infects and replicates in tumor cells The pela-initiated inflammatory response results in initiates an inflammatory response, through associating
Slide 5: Pelareorep Has Been Observed to Replicate in Almost All Evaluated Tumors
PELAREOREP HAS BEEN OBSERVED TO REPLICATE IN ALMOST ALL EVALUATED TUMORS Pela RNA is found in tumor but not stromal cells Pela is found in almost all on-treatment tumor biopsies Indication treated with IV Pela # of biopsied tumors # Pela-positive biopsies Pancreatic ductal 12 12 adenocarcinoma Metas
Slide 6: Pelareorep Single-Agent Activity
PELAREOREP SINGLE-AGENT ACTIVITY REO 004 and REO 005 - Dose escalation studies of IV pelareorep in refractory metastatic solid tumors REO 004 • Pelareorep: 1x108 to 3x1010 TCID50 per dose (N=18; Cancers: ovarian, colon, breast, cervical, sarcoma, • DCR = 45% (1 PR + 7 SD in 18 total patients) carcin
Slide 7: Broad Clinical Experience and Well-Understood Safety Results
BROAD CLINICAL EXPERIENCE AND WELL-UNDERSTOOD SAFETY RESULTS Pela has been >20 Oncolytics-sponsored studies Multiple cancer indications >1,200 patients treated, evaluated in and several externally sponsored (breast, pancreatic, colorectal, including >300 patients studies (NCI, CCTG, etc.) myeloma, b
Slide 8: Market Opportunity Within Pelareorep's Targeted Indications
MARKET OPPORTUNITY WITHIN PELAREOREP’S TARGETED INDICATIONS Gastrointestinal cancer is the fastest growing cancer in the world in people under 50 years old • ~ 1,900,000 patients globally 4 2L Metastatic • ~ $20 billion total addressable market with 4.7% CAGR to 2033 5 Colorectal Cancer (mCRC) • RAS
Slide 9: Pelareorep Clinical Development
PELAREOREP CLINICAL DEVELOPMENT
Slide 10: Clinical POC Across Targeted Indications Guides Strategic Sequencing
CLINICAL POC ACROSS TARGETED INDICATIONS GUIDES STRATEGIC SEQUENCING Targeted indication SOC benchmark* Pela Data Delta OS: 11.2 mo, PFS: 5.7 mo OS: 27 mo, PFS: 16.6 mo 2L mCRC (RAS-mutated) ~ 2-3x ORR: 6-11%1,2 ORR: 33%9 ORR: 11-24%3-6 ORR: 30% ≥2L SCAC ~ 1.5-3x DOR: 9.5 months3 DOR: 17 months 1L m
Slide 11: Clinical Development Pipeline
CLINICAL DEVELOPMENT PIPELINE Near-term rare disease opportunity in SCAC and long-term platform expansion in CRC and PDAC Program Collaborator Combination Phase 1 Phase 2 Registration-Enabling Phase 3 Anticipated Milestone 2L CRC RAS-mutated chemo + bev TBD Launch 1H 2026 Biomarker-focused study +/-
Slide 12: Colorectal Cancer Program
COLORECTAL CANCER PROGRAM *Received FDA Fast Track Designation
Slide 13: Efficacy Results for Pelareorep in Colorectal Cancer Across Multiple Studies
EFFICACY RESULTS FOR PELAREOREP IN COLORECTAL CANCER DEMONSTRATED ACROSS MULTIPLE STUDIES REO 022 study in 2L KRAS mutant mCRC results more than double historical third-party benchmarks1, 2, 3: • PFS: 16.6 months vs 5.7 months (pelareorep + FOLFIRI + bevacizumab vs. FOLFIRI + bevacizumab) • OS: 27.0
Slide 14: REO 022 Study of Pelareorep in ≥2L KRAS-mutant MSS mCRC
REO 022 STUDY OF PELAREOREP IN ≥2L KRAS-mutant MSS mCRC The combination of pelareorep with SOC equates to ORR, PFS, and OS that is 2-3X SOC Design Phase 1 dose escalation FOLFIRI + anti-VEGF 15 Part B patients; Metastatic or advanced KRAS- Population FOLFIRI mutated colorectal cancer; Refractory to
Slide 15: Anal Cancer Program
ANAL CANCER PROGRAM
Slide 16: Pela + Atezo in ≥2L SCAC
PELA + ATEZO IN ≥2L SCAC Strong efficacy signal with immunotherapy combination without chemo in difficult cancer 160% PD 140% 128% PD 120% 100% PD Tumor Response % Change From Baseline 100% 79% PD • 30% ORR in 20 evaluable ≥2L patients 80% 60% PD PD PD 60% 50% 45% 41% PD PD PD PD • 29% ORR in 14 eva
Slide 17: Pancreatic Cancer Program
PANCREATIC CANCER PROGRAM *Received FDA Fast Track & Orphan Drug Designations
Slide 18: Consistent Survival Benefit Observed in Multiple 1L mPDAC Studies
CONSISTENT SURVIVAL BENEFIT OBSERVED IN MULTIPLE 1L MPDAC STUDIES Clinical results of pelareorep in first-line mPDAC studies Company (Study) Description (Patients) 1-Year Survival 2-Year Survival Notes DCR: 83% vs. 33% Oncolytics Pelareorep + Gemcitabine (REO 017) 45% vs. 22% 24% vs. 4% Single arm v
Slide 19: 2-Year Survival Rates in 1L Metastatic PDAC: Comparison to Landmark Studies
2-YEAR SURVIVAL RATES IN 1L METASTATIC PDAC: COMPARISON TO LANDMARK STUDIES 2-year Study 2-year Survival Rate survival 0% 10% 20% 30% Pela-based 21.9% REO 017: Pela + G therapy Pela-based 24.0% Comparator NCI 8601: Pela + CP therapy 20.0% Weighted mean = 21.9% treatment 9.2% arms (n=9) Conroy: FOLFI
Slide 20: Regulatory, Intellectual Property and Manufacturing
REGULATORY, INTELLECTUAL PROPERTY AND MANUFACTURING
Slide 21: Regulatory Strategy Based on Extensive Clinical Data
REGULATORY STRATEGY BASED ON EXTENSIVE CLINICAL DATA Trial Activities Indication Design Regulatory Strategy (estimated) • Proof of concept solidly established in three GI tumors Randomized; 2L CRC 1H 2026 • Focus on most efficient regulatory path in high unmet Sponsored medical need indications with
Slide 22: IP Profile and Manufacturing Characteristics
IP PROFILE AND MANUFACTURING CHARACTERISTICS Intellectual Property Manufacturing • 149 patents issued worldwide • Non-genetically modified Reovirus • New patents expected to extend manufacturing • No special handling requirements and method of use protection into 2044 • High yield and low COGs • Com
Slide 23: Innovative Leadership Team with Strong Immuno-Oncology Expertise
INNOVATIVE LEADERSHIP TEAM WITH STRONG IMMUNO-ONCOLOGY, BUSINESS DEVELOPMENT, CLINICAL TRIAL AND FINANCE EXPERTISE Transactional expert Over 20 years of finance Nearly 30 years of drug having led more than 50 and accounting expertise development experience deals, including $2 billion focused on biot
Oncolytics Biotech — Investor Presentation (March 2026) on 6ix